common.study.topics.clinical

Fat Metabolism

common.study.values.description

L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

The gut is able to retain some fat for many hours after a fatty meal. The gut hormone glucagon-like peptide-2 (GLP-2) is known to release these fat stores in the gut, but it is not known how GLP-2 achieves this. One possibility is that GLP-2 increases blood flow in the gut. NG-monomethyl-L-arginine (L-NMMA) is a substance that inhibits nitric oxide synthase (an enzyme that helps make nitric oxide which increases blood flow). This protocol examines whether blocking gut blood flow with L-NMMA is able to prevent GLP-2 from releasing gut lipid stores. Healthy participants will be treated with a combination of Teduglutide (a resistant form of GLP-2) and L-NMMA, and their respective controls. Blood lipid levels will be measured following treatments.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Teduglutide + Normal Saline

Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion

Drug - Teduglutide + L-NMMA

Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion

Drug - Placebo + L-NMMA

Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion

participant.views.study.view.additional

participant.views.study.view.scientific-title

Role of a Nitric Oxide Synthase Inhibitor on GLP-2 Mediated Intestinal Lipoprotein Release

common.study.values.clinical-trial-id

NCT03534661

participant.views.study.view.id

xboNYa